VirTech Bio has been awarded a twelve-month, $1.4 million contract modification through the Medical Technology Enterprise Consortium (MTEC) to advance manufacturing scale-up of OxyBridge™ toward clinical-grade production.
VirTech Bio has selected GBI Biomanufacturing of Plantation, Florida, as the contract development and manufacturing organization (CDMO) for OxyBridge™, its hemoglobin-based oxygen carrier for hemorrhagic shock.
VirTech Bio has been granted two further patents covering OxyBridge™ this year, bringing the company's issued patent portfolio to four across the United States, Europe and Australia.
VirTech Bio CEO Dr. Dallas Hack presented OxyBridge™ at the 2025 Military Health System Research Symposium, held from 4 to 7 August 2025 at the Gaylord Palms Resort in Kissimmee, Florida.
At a second Pre-IND meeting with the US Food and Drug Administration in March 2024, VirTech Bio received agreement on the design of the Phase I clinical trial for OxyBridge™, its hemoglobin-based oxygen carrier for hemorrhagic shock.
We are happy to announce the expansion of our Scientific Advisory Board with two esteemed professionals and leaders in their fields.
As we begin the new year, I would like to share the significant progress we have made during 2022.
COL(R) Dallas Hack, MD, CEO of VirTech Bio, will present the advancements of OxyBridge™ at the Florida Venture Summit in Miami.
Solution is tested to give an organ donated for transplant longer survival and to help victims of accidents
Português
Solução é testada para dar maior sobrevida a órgão doado para transplante e para socorrer acidentados
VirTech Bio, creators of OxyBridge™, announced the appointment of COL(R) Dallas Hack, MD, as their new CEO, March 17, 2022.